'To block or not to block'; whether to continue renin-angiotensin-aldosterone system blockade in advanced chronic kidney disease

摘要

With the emergence of novel potassium-binding agents, it is possible that clinicians will attempt to control serum potassium rather than withdraw ACE/ARB therapy, particularly in patients with underlying cardiovascular diseasea.